E Fund Management’s Heron Therapeutics HRTX Stock Holding History

E Fund Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15,642	Closed	-$54.7K	–	364
2024 Q2	$54.7K	Buy	+15,642	New	+$48.1K	﹤0.01%	316
2022 Q4	–	Sell	-41,391	Closed	-$175K	–	343
2022 Q3	$175K	Sell	41,391 -45,190	-52%	-$177K	0.02%	314
2022 Q2	$242K	Buy	86,581 +38,818	+81%	+$156K	0.02%	264
2022 Q1	$273K	Buy	47,763 +29,396	+160%	+$215K	0.01%	229
2021 Q4	$168K	Buy	18,367 +3,562	+24%	+$36.4K	0.01%	275
2021 Q3	$158K	Buy	+14,805	New	+$180K	0.01%	244

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

E Fund Management's HRTX Position: Q3 2024 in Review

E Fund Management sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 15,642 shares — an estimated $54.7K sold.

E Fund Management first reported a position in HRTX in Q3 2021 and held it in 6 quarters. The position peaked at $273K in Q1 2022. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

E Fund Management reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
E Fund Management sold 15,642 Heron Therapeutics shares in Q3 2024, an estimated $54.7K.
E Fund Management first reported a position in Heron Therapeutics in Q3 2021 and held it in 6 quarters.
E Fund Management's Heron Therapeutics position peaked at $273K in Q1 2022.
173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on E Fund Management's 13F filing for Q3 2024, filed 13 Nov 2024.